MLP Oncología
@MLPOncoData
Followers
701
Following
409
Media
1K
Statuses
5K
Medicina Interna - Oncología #OncTwitter
Medellín, Colombia
Joined January 2012
Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data
jamanetwork.com
This prognostic study characterizes the incidence of chronic kidney disease after cisplatin treatment and evaluates prediction models.
0
0
0
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
nejm.org
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3 tri...
0
0
0
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial 🚫☢️
ascopubs.org
PURPOSETo determine the benefit, measured as complete removal of a tumor so that no tumor cells are detectable during histopathologic examination of the resection margin (R0 resection rate), of...
0
0
1
“Los fines de semana no se huye de la vida, se construye una vida de la que no se necesite huir”.
0
0
6
ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER+HER2– breast cancer
nature.com
Nature Reviews Clinical Oncology - ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER+HER2– breast cancer
0
0
0
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial
0
0
0
In comparative studies, PCR-GGI showed strong correlation with other proliferation-based signatures (e.g., Oncotype DX proliferation module, Spearman’s ρ = 0.85, p < 0.001), but it focuses solely on proliferation, unlike Oncotype DX’s broader 21-gene panel.
1
0
0
The **Polymerase Chain Reaction-Genomic Grade Index (PCR-GGI)**, specifically the **Ipsogen MapQuant Dx** assay, is a qRT-PCR-based test designed to assess tumor grade and proliferation in breast cancer, particularly for hormone receptor-positive (HR+) early-stage disease.
2
0
1
"Si matas una cucaracha eres un héroe. Si matas una mariposa eres malo. La moral tiene criterios estéticos". FN.
0
0
2
Artificial intelligence across the cancer care continuum
acsjournals.onlinelibrary.wiley.com
This review highlights the expanding role of artificial intelligence across the cancer care continuum, from risk prediction to end-of-life care. It emphasizes both the promise of artificial intelli...
0
0
3
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
nature.com
Nature Reviews Clinical Oncology - Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage driver-negative non-small-cell lung cancer (NSCLC), although...
0
0
1
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
thelancet.com
Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter despite substantial non-adherence. Longer follow-up would have been needed to help assess directly...
0
0
0
Clinical and Economic Research of Bone Modifiers as Adjuvant Therapy for Early Breast Cancer: A Systematic Literature Review: Insufficient clinical and economic evidence. De los expertos, líbrame Señor❗️
thebreastonline.com
Adjuvant bisphosphonate therapy is recommended by some guidelines for postmenopausal breast cancer, but its application is not ideal due to inconsistent study results and economic burden considerat...
1
1
1
Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A #metaanalysis of phase III trials
0
0
1
Older Age Threshold for Oxaliplatin Benefit in Stage II to III Colorectal Cancer
jamanetwork.com
This cohort study investigates whether the addition of oxaliplatin to adjuvant chemotherapy for stage II to III colorectal cancer is associated with improved survival at age thresholds from 60 to 80...
0
0
1